EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Dissemination of EFFORT trial results in Indonesia: a stakeholder meeting report on tafenoquine and primaquine for radical cure of Plasmodium vivax

Ayodhia Pitaloka Pasaribu, Vincent Jimanto, Framita Ainur, Novita Rohdearni Saragih, Halik Hadi, Dedi Sahat Parningotan Siagian, Budi Junaraman Sinaga, Ari Winasti Satyagraha, Ferdinand J Laihad, Ajib Diptyanusa, Reynold Rizal Ubra, Obet Tekege und 27 weitere

Malaria Journal · 27.05.2026 · 25 (1)

DOI: 10.1186/s12936-026-05948-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Malaria Journal, online erschienen am 27.05.2026. Verfasst von Ayodhia Pitaloka Pasaribu und 38 weiteren Autor:innen. Beteiligte Einrichtung: Medical Faculty, Universitas Sumatera Utara, Medan, Indonesia. Hauptthemen laut MEDLINE: Primaquine, Malaria, Vivax, Antimalarials, Aminoquinolines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: World Health Organization, National Health and Medical Research Council, Gates Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The EFFORT clinical trial was conducted in four countries (Cambodia, Ethiopia, Indonesia, and Pakistan) to evaluate the safety and effectiveness of high-dose primaquine (7 mg/kg over 7 days) and single-dose tafenoquine (300 mg) compared with the standard 14-day low-dose primaquine regimen for the radical cure of patients with Plasmodium vivax malaria. In Indonesia, both regimens were co-administered with dihydroartemisinin–piperaquine. This paper reports on a national stakeholder meeting held in May 2025 to disseminate Indonesia-specific findings and discuss their implications for malaria control and elimination policy. Discussions centred on (i) the evidence gaps regarding tafenoquine when combined with artemisinin combination therapies (ACTs), (ii) the feasibility of implementing high-dose primaquine in Indonesia as a near-term option, and (iii) the need for subnational strategies that reflect the country’s diverse epidemiological context. Stakeholders highlighted the need for further studies on tafenoquine with ACTs, while recognising high-dose primaquine as an immediately implementable option pending strengthened G6PD testing. The discussion emphasised the importance of tailoring strategies to Indonesia’s diverse settings, supported by strong political commitment to elimination.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PrimaquineMalaria, VivaxAntimalarialsAminoquinolinesPlasmodium vivaxIndonesiaHumansArtemisinins

Substanzen

PrimaquinetafenoquineAntimalarialsAminoquinolinesArtemisinins

Autor:innen und Institutionen

  • Medical Faculty, Universitas Sumatera Utara, Medan, Indonesia.
  • Yayasan Penguatan Kesehatan Masyarakat Tridarma, Medan, Indonesia.
  • Provincial Health Office, Medan, North Sumatra, Indonesia.
  • District Health Office, Batu Bara Regency, Indonesia.
  • Eijkman Research Center for Molecular Biology, National Research and Innovation Agency, Cibinong, Indonesia.
  • EXEINS Health Initiative, Jakarta, Indonesia.

Förderung

  • World Health Organization
  • National Health and Medical Research Council
  • Gates Foundation
  • Bill and Melinda Gates Foundation

Zitieren

APA

Pasaribu, A. P., Jimanto, V., Ainur, F., Saragih, N. R., Hadi, H., Siagian, D. S. P., Sinaga, B. J., Satyagraha, A. W., Laihad, F. J., Diptyanusa, A., Ubra, R. R., Tekege, O., Darmayanti, L., Herdiana, H., Adella, J., Mannion, K., Curry, E., Poespoprodjo, J. R., Kenangalem, E., …, & Thriemer, K. (2026). Dissemination of EFFORT trial results in Indonesia: a stakeholder meeting report on tafenoquine and primaquine for radical cure of Plasmodium vivax. Malaria Journal, 25(1). https://doi.org/10.1186/s12936-026-05948-3

Vancouver

Pasaribu AP, Jimanto V, Ainur F, Saragih NR, Hadi H, Siagian DSP, et al. Dissemination of EFFORT trial results in Indonesia: a stakeholder meeting report on tafenoquine and primaquine for radical cure of Plasmodium vivax. Malaria Journal. 2026;25(1). doi:10.1186/s12936-026-05948-3

BibTeX
@article{Pasaribu2026,
  author = {Pasaribu, Ayodhia Pitaloka and Jimanto, Vincent and Ainur, Framita and Saragih, Novita Rohdearni and Hadi, Halik and Siagian, Dedi Sahat Parningotan and Sinaga, Budi Junaraman and Satyagraha, Ari Winasti and Laihad, Ferdinand J and Diptyanusa, Ajib and Ubra, Reynold Rizal and Tekege, Obet and Darmayanti, Lusi and Herdiana, Herdiana and Adella, Jacklyn and Mannion, Kylie and Curry, Ella and Poespoprodjo, Jeanne Rini and Kenangalem, Enny and Burdam, Faustina Helena and Sutanto, Inge and Nelwan, Erni Juwita and Ganadhi, Gabriel Jason and Shrestha, Bijaya and Mnjala, Hellen and Hawley, William A and Prameswari, Hellen Dewi and Theodora, Minerva and Silalahi, Fadjar Surya Mensing and Susanto, Hermawan and Immanuella, Febry and Puspadewi, Riskha Tiara and Fajariyani, Sri Budi and Samad, Iriani and Supriyanto, Dedy and Muhafilah, Nurul and Isa, Rahmad and Price, Ric N and Thriemer, Kamala},
  title = {Dissemination of EFFORT trial results in Indonesia: a stakeholder meeting report on tafenoquine and primaquine for radical cure of Plasmodium vivax},
  journal = {Malaria Journal},
  year = {2026},
  volume = {25},
  number = {1},
  doi = {10.1186/s12936-026-05948-3}
}
Kostenlos starten →